2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Tumors: new trials by email Literature Review of Tumors trials Research Report on Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone ramosetron, aprepitant, dexamethasone, palonosetron, aprepitant, dexamethasone - Cancer, Tumors | Phase 4 | Completed | Kangdong Sacred Heart Hospital | 292 | 2015-08-19 | 2018-05-11 |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Rasburicase (SR29142) - Tumors, Hyperuricemia | Phase 4 | Completed | Sanofi | 94 | 2004-03-01 | 2009-03-30 |
Neoplasms (2) · Hyperuricemia (1) · Leukemia (1) · Lymphoma (1) · Recurrence (1) · Tumor Lysis Syndrome (1) · Vomiting (1)
Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Signs and Symptoms (1) · Signs and Symptoms, Digestive (1)
Aprepitant (1) · Dexamethasone (1) · Palonosetron (1) · Urate Oxidase (1) · ramosetron (1) · rasburicase (1)
Kangdong Sacred Heart Hospital (1) · Sanofi (1)
South Korea (1) · United States (1)
Jin-Hyoung Kang, Ph.D (1) · Jung Hye Kwon, PhD (1)